指南与共识心脑血管急症创伤与烧伤消化、代谢与肾脏急症

亚太地区轻度创伤性脑损伤诊断及血液生物标志物临床整合共识声明:一项改良德尔菲研究

Consensus statements for the diagnosis of mild traumatic brain injury and clinical integration of blood-based biomarkers in the Asia-Pacific region: a modified Delphi study.
指南 / 共识 · Int J Emerg Med · 2026-07-03
一句话结论亚太专家共识:GFAP和UCH-L1可在伤后12小时内作为临床评估的辅助工具,用于轻度创伤性脑损伤的分诊和减少可避免的CT检查。

该改良德尔菲研究由亚太地区急诊医学、神经外科和神经内科的十位专家参与,针对轻度创伤性脑损伤(mTBI)的定义、诊断路径及血液生物标志物(GFAP和UCH-L1)的临床整合制定共识。经过两轮匿名投票和面对面会议,最终11条声明在第二轮投票中达成90%至100%的同意率,其中7条为100%同意。声明涵盖mTBI定义、GFAP和UCH-L1在伤后12小时内的辅助诊断作用、在抗凝和中毒等诊断困难亚组中的效用,以及临床评估和本地影像路径在分诊、影像、出院和随访决策中的首要地位。共识认为这些生物标志物作为临床评估和既定影像决策的辅助手段,可能有助于减少可避免的CT检查并支持特定患者的分诊。

要点

  • 共识声明:GFAP和UCH-L1可作为临床评估的辅助工具,用于伤后12小时内mTBI的诊断评估。
  • 共识声明:在抗凝和中毒等诊断困难亚组中,GFAP和UCH-L1具有辅助诊断效用。
  • 共识声明:临床评估和本地影像路径仍是指导分诊、影像、出院和随访决策的首要依据。
  • 共识认为生物标志物作为辅助手段可能减少可避免的CT检查并支持特定患者的分诊。
  • 全部11条声明在第二轮投票中达成90%至100%的同意率,其中7条为100%同意。

适用人群与场景

  • 亚太地区急诊科就诊的疑似轻度创伤性脑损伤(mTBI)患者。
  • 诊断困难亚组包括抗凝患者和中毒患者。

诊断标准与关键阈值

  • 共识声明涉及创伤性脑损伤(TBI)和mTBI的定义。

处置流程与药物剂量

  • 共识声明:GFAP和UCH-L1在伤后12小时时间窗内作为辅助诊断工具整合入mTBI评估路径。
  • 共识声明:临床评估和本地影像路径继续作为指导分诊、影像检查、出院和随访决策的首要依据。
  • 共识认为生物标志物作为临床评估和既定影像决策的辅助手段,可能有助于减少可避免的CT检查并支持特定患者的分诊。

研究设计与关键结果

  • 研究类型:改良德尔菲研究;专家小组:十位来自亚太地区(澳大利亚、印度、印度尼西亚、菲律宾、新加坡、台湾、泰国)急诊医学、神经外科和神经内科的专家。
  • 方法:针对性文献回顾形成34条初步声明,整合为11条声明,专家使用4点李克特量表进行两轮匿名在线投票,共识定义为≥70%同意率;2025年5月在曼谷面对面会议审查投票结果并修订声明后进行第二轮投票。
  • 结果:全部11条最终共识声明在第二轮投票后达成90%至100%的同意率,其中7条达到100%同意,4条达到90%同意。

证据类型、等级与局限

  • 证据类型:改良德尔菲专家共识。
  • 共识定义:≥70%同意率。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 共识声明支持将GFAP和UCH-L1作为伤后12小时内mTBI评估的辅助工具,与临床评估和本地影像路径联合使用。
  • 共识声明强调临床评估和本地影像路径在分诊、影像、出院和随访决策中仍居首要地位,生物标志物不能替代临床评估。
  • 共识认为生物标志物作为辅助手段可能减少可避免的CT检查并支持特定患者的分诊。
  • 共识声明旨在支持本地化适配的方案以及未来亚太地区特定的实施和验证研究。

指南或共识出处

  • 共识声明:亚太地区轻度创伤性脑损伤诊断及血液生物标志物临床整合共识声明(改良德尔菲研究),发表于Int J Emerg Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Timely and accurate diagnosis of mild traumatic brain injury (mTBI) remains challenging in acute care. In the Asia-Pacific (APAC) region, marked heterogeneity in healthcare infrastructure, computed tomography (CT) utilization, and diagnostic pathways underscores the need for practical, standardized approaches to assessment. Blood-based biomarkers, particularly glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), have shown promising diagnostic performance and have been incorporated into clinical pathways in other regions. However, their role in APAC emergency care workflows has not been systematically addressed. This study aimed to develop expert consensus on the definition, diagnosis, and clinical integration of these biomarkers into mTBI assessment across APAC.

METHODS: A structured modified Delphi process was employed, involving ten expert panelists representing emergency medicine, neurosurgery, and neurology from APAC countries including Australia, India, Indonesia, the Philippines, Singapore, Taiwan, and Thailand. A targeted literature review informed the development of 34 preliminary statements, consolidated into 11 statements covering mTBI definition, diagnostic approach, and biomarker integration. Panelists rated each statement using a 4-point Likert scale across two anonymous online voting rounds, with consensus defined as ≥ 70% agreement. Voting results were reviewed at a face-to-face meeting in Bangkok in May 2025, where statements were refined before Round 2 voting.

RESULTS: All 11 final consensus statements achieved agreement ratings of 90% to 100% following Round 2 voting. Seven statements reached 100% agreement and four achieved 90% agreement. Statements addressed definitions of TBI and mTBI, the adjunctive diagnostic role of GFAP and UCH-L1 within a 12-hour post-injury window, their utility in diagnostically challenging subgroups such as anticoagulated and intoxicated patients, and the continued primacy of clinical assessment and local imaging pathways in guiding triage, imaging, discharge, and follow-up decisions.

CONCLUSIONS: This modified Delphi study produced 11 high-consensus statements that provide a regional framework for the diagnosis of mTBI and for integration of GFAP and UCH-L1 into biomarker-supported assessment pathways across APAC. These biomarkers may help reduce avoidable CT imaging and support triage in selected patients when used as adjuncts to clinical assessment and established imaging decision-making. The statements are intended to support locally adapted protocols and future APAC-specific implementation and validation studies.

来源:Int J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kuan WS, Veerasarn K, Joseph M, et al. Consensus statements for the diagnosis of mild traumatic brain injury and clinical integration of blood-based biomarkers in the Asia-Pacific region: a modified Delphi study. Int J Emerg Med. 2026. PMID: 42399783. doi:10.1186/s12245-026-01292-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。